Quantum Immunologics (QI) has announced that the first patient in its breast cancer trial has begun to receive its dendritic cell therapy.
QI is currently sponsoring and conducting an FDA-authorized phase I/II clinical trial. It is to test the safety and efficacy of its immunotherapy on 27 Stage IV breast cancer patients, who have failed conventional therapy.
Chuck Broes, CEO of QI, said: This achievement marks a significant milestone in the life cycle of our company, and we look forward with great hope and commitment as we aspire to a successful trial outcome.
The clinical trials involve the use of dendritic cell therapy using the oncofetal antigen (OFA), or iLRP – immature Laminin Receptor Protein, as a cancer antigen. QI believes that the OFA antigen can serve as a valuable and promising antigen for individualized breast cancer immunotherapy.